TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11426667

Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered twice weekly (group 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered thrice weekly (group 3)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered once weekly (group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All regimens (group 1, group 2, group 3)
Number of subjects: 33
Study: 9471914

Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination of the internal genital organs
Number of subjects: 248

Group type: COMPARATOR
Intervention: Ultrasonographic examination of the first- and second-rate genital features
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination
Number of subjects: 248
Study: 8509579

Group type: EXPERIMENTAL
Intervention: Beclomethasone (500 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2879970

Group type: EXPERIMENTAL
Intervention: Chlorproguanil 20 mg weekly
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 30500138

Group type: EXPERIMENTAL
Intervention: Topical methyl estradiolpropanoate (MEP), applied twice daily for 14 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study: 26688437

Group type: EXPERIMENTAL
Intervention: Structural group therapy (12 sessions for six weeks, 1 hour, two times per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Handicraft group (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Structural group therapy
Number of subjects: 60
Study: 24663049

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) 50 mg/m²/d for 10 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Azacitidine (AZA) 50 mg/m²/d for 10 days + entinostat 4 mg/m²/d on day 3 and day 10
Number of subjects: 149
Study: 23457678

Group type: EXPERIMENTAL
Intervention: Inhaled menthol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham inhalation
Number of subjects: 10
Study: 19229268

Group type: EXPERIMENTAL
Intervention: Tear film break‐up time test
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Schirmer test
Number of subjects: 140
Study: 18378757

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Metformin plus clomiphene
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Clomiphene alone
Number of subjects: 1639
Study: 16834487

Group type: EXPERIMENTAL
Intervention: Selective DA D2 receptor antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12587101

Group type: EXPERIMENTAL
Intervention: Adaptive stratification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stratified random blocks
Number of subjects: 0
Study: 11000587

Group type: EXPERIMENTAL
Intervention: Harmonic power Doppler imaging during LV contrast enhancement (Optison or Definity DMP115)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Harmonic power Doppler imaging
Number of subjects: 22
Study: 9031393

Group type: EXPERIMENTAL
Intervention: Quinine 600 mg tid for 5 days + Tetracycline 250 mg qid for 7 days (Q5T7; group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quinine 600 mg tid for 7 days + Tetracycline 250 mg qid for 7 days (Q7T7; group B)
Number of subjects: 90
Study: 1688971

Group type: EXPERIMENTAL
Intervention: Intravenous dibutyryl cyclic AMP (DBcyclicAMP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine
Number of subjects: 9
Study: 379937

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 65
Study: 31622155

Group type: EXPERIMENTAL
Intervention: HealthLinks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HealthLinks+
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed control
Number of subjects: 68
Study: 28722627

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) performed by Community Health Workers (CHWs) for malaria screening and treatment with artemether‐lumefantrine.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) alone without additional screening by CHWs.
Number of subjects: 0
Study: 26032570

Group type: EXPERIMENTAL
Intervention: Continuous exercise (CE, 30‐min cycling)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Accumulated exercise with 10‐min intervals (AE10, 3 × 10‐min cycling, 10‐min interval)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Accumulated exercise with 60‐min intervals (AE60, 3 × 10‐min cycling, 60‐min interval)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 19
Study: 23238861

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 231
Study: 21667207

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 786

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Stage I tumor
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Stage II tumor
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Stage III tumor
Number of subjects: 786
Study: 19562913

Group type: EXPERIMENTAL
Intervention: DETERMINE kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DIASPOT kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDBIOLINE kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DIALAB Elisa kit
Number of subjects: 0
Study: 15647671

Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT immediately after stereotactic irradiation (STI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stereotactic irradiation (STI)
Number of subjects: 16
Study: 12605289

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg daily for 6 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg daily for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9797199

Group type: EXPERIMENTAL
Intervention: 1.5 mg indapamide sustained‐release coated tablets
Number of subjects: 576

Group type: COMPARATOR
Intervention: 20 mg enalapril
Number of subjects: 576
Study: 7648464

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2757957

Group type: EXPERIMENTAL
Intervention: Topical psoralen photochemotherapy (topical PUVA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional superficial radiotherapy
Number of subjects: 21
Study: 619946

Group type: EXPERIMENTAL
Intervention: Tubocurarine (0.05 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suxamethonium (0.08 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (before drug administration)
Number of subjects: 0
Study: 31868024

Group type: EXPERIMENTAL
Intervention: Uphill treadmill walking plus physical therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 30
Study: 31892500

Group type: EXPERIMENTAL
Intervention: Rewarded video advertising
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no advertising)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Banner advertising
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Advergame
Number of subjects: 156
Study: 30509312

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1) plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1) plus chemotherapy
Number of subjects: 0
Study: 27329967

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) deficiency
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Protein C (PC) deficiency
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Protein S (PS) deficiency
Number of subjects: 161

Group type: COMPARATOR
Intervention: No thrombophilia
Number of subjects: 161
Study: 25899314

Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg preoperative dose)
Number of subjects: 200
Study: 23878845

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution (Concepsis, Ultradent) applied on the etched dentin for 60 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etch-and-rinse resin adhesive (Single Bond, 3M ESPE) and universal microhybrid composite resin (Filtek Z250, 3M ESPE)
Number of subjects: 30
Study: 20670960

Group type: EXPERIMENTAL
Intervention: Starion tissue welding system
Number of subjects: 98

Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 98
Study: 18853470

Group type: EXPERIMENTAL
Intervention: In-home geriatric assessment and management programme
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 15920181

Group type: EXPERIMENTAL
Intervention: P-LMA
Number of subjects: 30

Group type: COMPARATOR
Intervention: C-LMA
Number of subjects: 30
Study: 12892690

Group type: EXPERIMENTAL
Intervention: Large pad loss (42 g)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Small pad loss (7 g)
Number of subjects: 315
Study: 10481920

Group type: EXPERIMENTAL
Intervention: 900 mg Kwai garlic
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8991966

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 100

Group type: COMPARATOR
Intervention: No caffeine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Caffeine (for smokers)
Number of subjects: 100
Study: 2006600

Group type: EXPERIMENTAL
Intervention: Clonidine premedication (3.5 micrograms.kg‐1) and postoperative i.v. infusion (0.3 microgram.kg‐1.h‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10252496

Group type: EXPERIMENTAL
Intervention: Linear self-instructional program on the nature and treatment of IHD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no program)
Number of subjects: 100
Study: 30714812

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mindfulness-based strengths practice (MBSP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 63
Study: 27696703

Group type: EXPERIMENTAL
Intervention: Personalized supervised physical therapy program (1 month duration)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (could include ambulatory physical therapy)
Number of subjects: 220
Study: 26102168

Group type: EXPERIMENTAL
Intervention: Supporting Play Exploration and Early Development Intervention (SPEEDI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SPEEDI
Number of subjects: 10
Study: 24364223

Group type: EXPERIMENTAL
Intervention: Low energy UVB irradiation for 30 minutes a day for two weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22096049

Group type: EXPERIMENTAL
Intervention: Community Popular Opinion Leaders (CPOLs) intervention model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control and quality assurance (QC/QA) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative partnership relations
Number of subjects: 0
Study: 19551762

Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/day) and Aripiprazole (30 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topiramate and Aripiprazole combination
Number of subjects: 13
Study: 17580388

Group type: EXPERIMENTAL
Intervention: Long alternate day regimen of steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroids according to ISKDC regimen
Number of subjects: 0
Study: 15562202

Group type: EXPERIMENTAL
Intervention: Statin therapy (0.4 mg cerivastatin daily, later replaced by 20 mg simvastatin)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 250
Study: 10677093

Group type: EXPERIMENTAL
Intervention: Beta carotene, 50 mg, on alternate days
Number of subjects: 22071
Study: 9347403

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich snacks (100/0/0, 70/29/1, and 35/3/62 energy percent carbohydrate/fat/protein)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich snacks
Number of subjects: 26
Study: 8442961

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: droperidol 0.025 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: isotonic saline (control)
Number of subjects: 45
Study: 3715980

Group type: EXPERIMENTAL
Intervention: Isoniazid daily at 20 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Isoniazid daily at 12 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampicin administered twice a week
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All regimens (including steroids)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Stage of admission
Number of subjects: 180
Study: 30064406

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy combined with bevacizumab
Number of subjects: 106

Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 106
Study: 26228516

Group type: EXPERIMENTAL
Intervention: Esophageal dilation
Number of subjects: 31

Group type: COMPARATOR
Intervention: No dilation (control)
Number of subjects: 31
Study: 25531146

Group type: EXPERIMENTAL
Intervention: Low-salt diet (LSD)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Low-salt diet (LSD) with protein restriction
Number of subjects: 202
Study: 23285702

Group type: EXPERIMENTAL
Intervention: 500 mg cefuroxime axetil film-coated tablets (test product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinnat manufactured by GlaxoSmithKline Export Ltd. (reference product)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference products
Number of subjects: 0
Study: 20630128

Group type: EXPERIMENTAL
Intervention: High serum alkaline phosphatase (>= 97 IU/l)
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Low serum alkaline phosphatase (< 97 IU/l)
Number of subjects: 1827
Study: 18798231

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) with concomitant temozolomide (TMZ) at 75 mg/m²/day for 10 days, followed by TMZ at 75 mg/m²/day for 21 days every 4 weeks for up to 12 cycles
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) with concomitant temozolomide (TMZ)
Number of subjects: 27
Study: 15929959

Group type: EXPERIMENTAL
Intervention: Hypersensitivity pneumonitis (HP) patients
Number of subjects: 32
Study: 12052017

Group type: EXPERIMENTAL
Intervention: Out-of-school condition (three computer-tailored letters sent to students' homes)
Number of subjects: 3349

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3349

Group type: EXPERIMENTAL
Intervention: In-school condition (existing seven-lesson program)
Number of subjects: 3349

Group type: EXPERIMENTAL
Intervention: Combined approach (in-school and out-of-school)
Number of subjects: 3349
Study: 10465076

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5000 IU retinyl palmitate and 30 mg beta-carotene during the third trimester, 200000 IU retinyl palmitate at delivery)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation among preterm deliveries
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo among preterm deliveries
Number of subjects: 728
Study: 7797790

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenges with egg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (12 infants with negative test results)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SPT results
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 33
Study: 2112405

Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg daily
Number of subjects: 20
Study: 428229

Group type: EXPERIMENTAL
Intervention: Ethynodiol diacetate tablets (3 batches)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard oral solution of norethisterone
Number of subjects: 12
Study: 30887549

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 42
Study: 30306953

Group type: EXPERIMENTAL
Intervention: Telerehabilitation system for individualized multipronged exercise programs
Number of subjects: 0
Study: 26993268

Group type: EXPERIMENTAL
Intervention: DVD-assisted counselling (DVD-C)
Number of subjects: 936
Study: 25070271

Group type: EXPERIMENTAL
Intervention: Behavioral intervention delivered via the Internet and Skype video chats, duration 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70
Study: 22327145

Group type: EXPERIMENTAL
Intervention: Remifentanil group (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 41
Study: 20012507

Group type: COMPARATOR
Intervention: No staple line reinforcement (group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Buttressing of the staple line with Gore Seamguard (group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Staple line suturing (group 3)
Number of subjects: 75
Study: 17587253

Group type: EXPERIMENTAL
Intervention: Midbrain area measurement in patients with PSP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Midbrain area/pons area ratio (A(ms)/A(pn) ratio) measurement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Morphometric measurements (linear, surface, and volumetric)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison with control subjects (healthy volunteers)
Number of subjects: 36
Study: 16285270

Group type: EXPERIMENTAL
Intervention: Tokens pronounced by patients with UVFP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tokens pronounced by normal male subjects
Number of subjects: 12
Study: 12048659

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS) with 60% intensity, 20 Hz frequency, and 2 seconds burst length.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS)
Number of subjects: 9
Study: 9579492

Group type: EXPERIMENTAL
Intervention: Meperidine (target plasma concentration of 1.2 microg/ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alfentanil (target plasma concentration of 0.2 microg/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study: 7659765

Group type: EXPERIMENTAL
Intervention: Active TRP depletion followed by intranasal cocaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham depletion followed by intranasal cocaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active TRP depletion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 12
Study: 2664664

Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 1064434

Group type: EXPERIMENTAL
Intervention: vincristine‐‐prednisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: cytosine arabinoside‐‐6‐thioguanine
Number of subjects: 32
Study: 6251114

Group type: EXPERIMENTAL
Intervention: FK 33824 (0.5 mg i.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31577356

Group type: EXPERIMENTAL
Intervention: Community Participation Transition After Stroke (COMPASS) intervention, which includes home modifications and strategy training delivered in the home.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Community Participation Transition After Stroke (COMPASS) intervention.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attentional control group.
Number of subjects: 180
Study: 29246769

Group type: EXPERIMENTAL
Intervention: GAIN 3.0 educational program (flipped classroom model with e-learning and live interactive program)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: GAIN 3.0 educational program
Number of subjects: 416
Study: 26285025

Group type: EXPERIMENTAL
Intervention: Exercise + dual-task training (EDT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Exercise only (EO)
Number of subjects: 44
Study: 24287689

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 4
Study: 23373103

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide at a dose equivalent to the daily oral dose
Number of subjects: 308

Group type: COMPARATOR
Intervention: Higher doses of intravenous furosemide
Number of subjects: 308
Study: 19925270

Group type: EXPERIMENTAL
Intervention: Positive deviance strategy in the east unit during the second phase (July to September 2008)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control unit (west unit) during the second phase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Positive deviance strategy in the east unit during the second phase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both units during the third phase (October to December 2008)
Number of subjects: 40
Study: 16916856

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training programmes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioural therapy and exercise training programmes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored treatment approaches
Number of subjects: 0
Study: 15738537

Group type: EXPERIMENTAL
Intervention: FU/LV/bevacizumab
Number of subjects: 209

Group type: COMPARATOR
Intervention: FU/LV/placebo
Number of subjects: 209
Study: 11943033

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/day for 2 years and 10 mg/day for the remainder of the study)
Number of subjects: 3685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 3685